Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy

Detalhes bibliográficos
Autor(a) principal: Fillipe Luiz Rosado Carmo
Data de Publicação: 2020
Outros Autores: Houem Rabah, Barbara Fernandes Cordeiro, Sara Heloisa da Silva, Rafaela Miranda Pessoa, Simone Odília Antunes Fernandes, Valbert Nascimento Cardoso, Valérie Gagnaire, Martine Deplanche, Bruna Savassi, Alessandra Figueiroa, Emiliano Rosa Oliveira, Caio César Fonseca, Maria Izabel Alves Queiroz, Núbia Moraes Rodrigues, Sávio Henrique de Cicco Sandes, Álvaro Cantini Nunes, Luisa Lemos, Juliana de Lima Alves, Ana Maria Caetano Faria, Ênio Ferreira, Yves Le Loir, Gwénaël Jan, Vasco Azevedo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFMG
Texto Completo: http://hdl.handle.net/1843/40862
Resumo: Propionibacterium freudenreichii CIRM-BIA 129 (P. freudenreichii wild type, WT) is a probiotic bacterium, which exerts immunomodulatory effects. This strain possesses extractable surface proteins, including SlpB, which are involved in anti-inflammatory effect and in adhesion to epithelial cells. We decided to investigate the impact of slpB gene mutation on immunomodulation in vitro and in vivo. In an in vitro assay, P. freudenreichii WT reduced expression of IL-8 (p<0.0001) and TNF-α (p<0.0001) cytokines in LPS-stimulated HT-29 cells. P. freudenreichii ΔslpB, lacking the SlpB protein, failed to do so. Subsequently, both strains were investigated in vivo in a 5-FU-induced mucositis mice model. Mucositis is a common side effect of cytotoxic chemotherapy with 5-FU, characterized by mucosal injury, inflammation, diarrhea, and weight loss. The WT strain prevented weight loss, reduced inflammation and consequently histopathological scores. Furthermore, it regulated key markers, including Claudin-1 (cld1, p<0.0005) and IL-17a (Il17a, p<0.0001) genes, as well as IL-12 (p<0.0001) and IL-1β (p<0.0429) cytokines levels. Mutant strain displayed opposite regulatory effect on cld1 expression and on IL-12 levels. This work emphasizes the importance of SlpB in P. freudenreichii ability to reduce mucositis inflammation. It opens perspectives for the development of probiotic products to decrease side effects of chemotherapy using GRAS bacteria with immunomodulatory surface protein properties.
id UFMG_049d591a0356e49c5efdad478ad64485
oai_identifier_str oai:repositorio.ufmg.br:1843/40862
network_acronym_str UFMG
network_name_str Repositório Institucional da UFMG
repository_id_str
spelling Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapyProbioticMucositisSurface proteinImmunomodulationInflammationProbióticoMucositeQuimioterapiaPropionibacterium freudenreichii CIRM-BIA 129 (P. freudenreichii wild type, WT) is a probiotic bacterium, which exerts immunomodulatory effects. This strain possesses extractable surface proteins, including SlpB, which are involved in anti-inflammatory effect and in adhesion to epithelial cells. We decided to investigate the impact of slpB gene mutation on immunomodulation in vitro and in vivo. In an in vitro assay, P. freudenreichii WT reduced expression of IL-8 (p<0.0001) and TNF-α (p<0.0001) cytokines in LPS-stimulated HT-29 cells. P. freudenreichii ΔslpB, lacking the SlpB protein, failed to do so. Subsequently, both strains were investigated in vivo in a 5-FU-induced mucositis mice model. Mucositis is a common side effect of cytotoxic chemotherapy with 5-FU, characterized by mucosal injury, inflammation, diarrhea, and weight loss. The WT strain prevented weight loss, reduced inflammation and consequently histopathological scores. Furthermore, it regulated key markers, including Claudin-1 (cld1, p<0.0005) and IL-17a (Il17a, p<0.0001) genes, as well as IL-12 (p<0.0001) and IL-1β (p<0.0429) cytokines levels. Mutant strain displayed opposite regulatory effect on cld1 expression and on IL-12 levels. This work emphasizes the importance of SlpB in P. freudenreichii ability to reduce mucositis inflammation. It opens perspectives for the development of probiotic products to decrease side effects of chemotherapy using GRAS bacteria with immunomodulatory surface protein properties.Outra AgênciaUniversidade Federal de Minas GeraisBrasilFAR - DEPARTAMENTO DE ALIMENTOSFAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICASICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIAUFMG2022-04-06T22:39:21Z2022-04-06T22:39:21Z2020info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlepdfapplication/pdf10.18632/oncotarget.273191949-2553http://hdl.handle.net/1843/40862engOncotargetFillipe Luiz Rosado CarmoHouem RabahBarbara Fernandes CordeiroSara Heloisa da SilvaRafaela Miranda PessoaSimone Odília Antunes FernandesValbert Nascimento CardosoValérie GagnaireMartine DeplancheBruna SavassiAlessandra FigueiroaEmiliano Rosa OliveiraCaio César FonsecaMaria Izabel Alves QueirozNúbia Moraes RodriguesSávio Henrique de Cicco SandesÁlvaro Cantini NunesLuisa LemosJuliana de Lima AlvesAna Maria Caetano FariaÊnio FerreiraYves Le LoirGwénaël JanVasco Azevedoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMG2022-04-06T22:39:22Zoai:repositorio.ufmg.br:1843/40862Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2022-04-06T22:39:22Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.none.fl_str_mv Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy
title Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy
spellingShingle Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy
Fillipe Luiz Rosado Carmo
Probiotic
Mucositis
Surface protein
Immunomodulation
Inflammation
Probiótico
Mucosite
Quimioterapia
title_short Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy
title_full Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy
title_fullStr Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy
title_full_unstemmed Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy
title_sort Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy
author Fillipe Luiz Rosado Carmo
author_facet Fillipe Luiz Rosado Carmo
Houem Rabah
Barbara Fernandes Cordeiro
Sara Heloisa da Silva
Rafaela Miranda Pessoa
Simone Odília Antunes Fernandes
Valbert Nascimento Cardoso
Valérie Gagnaire
Martine Deplanche
Bruna Savassi
Alessandra Figueiroa
Emiliano Rosa Oliveira
Caio César Fonseca
Maria Izabel Alves Queiroz
Núbia Moraes Rodrigues
Sávio Henrique de Cicco Sandes
Álvaro Cantini Nunes
Luisa Lemos
Juliana de Lima Alves
Ana Maria Caetano Faria
Ênio Ferreira
Yves Le Loir
Gwénaël Jan
Vasco Azevedo
author_role author
author2 Houem Rabah
Barbara Fernandes Cordeiro
Sara Heloisa da Silva
Rafaela Miranda Pessoa
Simone Odília Antunes Fernandes
Valbert Nascimento Cardoso
Valérie Gagnaire
Martine Deplanche
Bruna Savassi
Alessandra Figueiroa
Emiliano Rosa Oliveira
Caio César Fonseca
Maria Izabel Alves Queiroz
Núbia Moraes Rodrigues
Sávio Henrique de Cicco Sandes
Álvaro Cantini Nunes
Luisa Lemos
Juliana de Lima Alves
Ana Maria Caetano Faria
Ênio Ferreira
Yves Le Loir
Gwénaël Jan
Vasco Azevedo
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Fillipe Luiz Rosado Carmo
Houem Rabah
Barbara Fernandes Cordeiro
Sara Heloisa da Silva
Rafaela Miranda Pessoa
Simone Odília Antunes Fernandes
Valbert Nascimento Cardoso
Valérie Gagnaire
Martine Deplanche
Bruna Savassi
Alessandra Figueiroa
Emiliano Rosa Oliveira
Caio César Fonseca
Maria Izabel Alves Queiroz
Núbia Moraes Rodrigues
Sávio Henrique de Cicco Sandes
Álvaro Cantini Nunes
Luisa Lemos
Juliana de Lima Alves
Ana Maria Caetano Faria
Ênio Ferreira
Yves Le Loir
Gwénaël Jan
Vasco Azevedo
dc.subject.por.fl_str_mv Probiotic
Mucositis
Surface protein
Immunomodulation
Inflammation
Probiótico
Mucosite
Quimioterapia
topic Probiotic
Mucositis
Surface protein
Immunomodulation
Inflammation
Probiótico
Mucosite
Quimioterapia
description Propionibacterium freudenreichii CIRM-BIA 129 (P. freudenreichii wild type, WT) is a probiotic bacterium, which exerts immunomodulatory effects. This strain possesses extractable surface proteins, including SlpB, which are involved in anti-inflammatory effect and in adhesion to epithelial cells. We decided to investigate the impact of slpB gene mutation on immunomodulation in vitro and in vivo. In an in vitro assay, P. freudenreichii WT reduced expression of IL-8 (p<0.0001) and TNF-α (p<0.0001) cytokines in LPS-stimulated HT-29 cells. P. freudenreichii ΔslpB, lacking the SlpB protein, failed to do so. Subsequently, both strains were investigated in vivo in a 5-FU-induced mucositis mice model. Mucositis is a common side effect of cytotoxic chemotherapy with 5-FU, characterized by mucosal injury, inflammation, diarrhea, and weight loss. The WT strain prevented weight loss, reduced inflammation and consequently histopathological scores. Furthermore, it regulated key markers, including Claudin-1 (cld1, p<0.0005) and IL-17a (Il17a, p<0.0001) genes, as well as IL-12 (p<0.0001) and IL-1β (p<0.0429) cytokines levels. Mutant strain displayed opposite regulatory effect on cld1 expression and on IL-12 levels. This work emphasizes the importance of SlpB in P. freudenreichii ability to reduce mucositis inflammation. It opens perspectives for the development of probiotic products to decrease side effects of chemotherapy using GRAS bacteria with immunomodulatory surface protein properties.
publishDate 2020
dc.date.none.fl_str_mv 2020
2022-04-06T22:39:21Z
2022-04-06T22:39:21Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv 10.18632/oncotarget.27319
1949-2553
http://hdl.handle.net/1843/40862
identifier_str_mv 10.18632/oncotarget.27319
1949-2553
url http://hdl.handle.net/1843/40862
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Oncotarget
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Minas Gerais
Brasil
FAR - DEPARTAMENTO DE ALIMENTOS
FAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS
ICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA
UFMG
publisher.none.fl_str_mv Universidade Federal de Minas Gerais
Brasil
FAR - DEPARTAMENTO DE ALIMENTOS
FAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS
ICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA
UFMG
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMG
instname:Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
instname_str Universidade Federal de Minas Gerais (UFMG)
instacron_str UFMG
institution UFMG
reponame_str Repositório Institucional da UFMG
collection Repositório Institucional da UFMG
repository.name.fl_str_mv Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv repositorio@ufmg.br
_version_ 1823248123433058304